Oncology Radiopharmaceuticals Market

A radiopharmaceutical starts decaying the moment it is made, so the supply chain has to deliver it in hours and the manufacturing network matters as much as the molecule. Douglas Insights values the oncology radiopharmaceuticals market at USD 10.1 billion in 2025 and expects USD 38.5 billion by 2035, compounding at 14.33%. The estimate is built from the bottom up: roughly 4.2 million oncology radiopharmaceutical patient doses administered in 2025 across diagnostic PET and SPECT cancer tracers, lutetium-177 targeted therapies, alpha emitter therapies, and associated isotope supply and radiopharmacy services, at an average realised price of USD 2,400 per dose, triangulated against procedure volumes, product sales and isotope supply data. Doses grow 11.0% a year as targeted radioligand therapies expand into earlier lines and new cancers, while realised price per dose rises 3.0% a year as the mix shifts toward high value therapeutics. This study sits within our nuclear medicine and radiopharmaceuticals coverage and follows the published Douglas Insights methodology.

Why did big pharma suddenly buy into radiopharmaceuticals?

Big pharma bought in after Novartis proved lutetium-177 therapy could sell: Bristol Myers Squibb paid about USD 4.1 billion for RayzeBio in February 2024 (BMS release) and AstraZeneca about USD 2.4 billion for Fusion Pharmaceuticals in June 2024 (AstraZeneca release), both for actinium-225 platforms aimed at cancers beyond prostate.

The underlying reason is that a new class of targeted cancer drugs proved it could work commercially at scale, and the largest drug companies decided they could not afford to be absent. Radiopharmaceuticals are drugs that carry a radioactive isotope; in the newest form, called radioligand therapy, a molecule designed to bind a protein found on cancer cells carries a radioactive payload that delivers radiation directly to tumours wherever they are in the body, sparing much of the surrounding healthy tissue. The same targeting molecule paired with a diagnostic isotope lets doctors image which patients’ tumours express the target before treating them, a pairing often called theranostics. Lutetium-177 therapies for neuroendocrine tumours and, more significantly, for advanced prostate cancer targeting the prostate specific membrane antigen, demonstrated clinical benefit and rapid commercial uptake, with the prostate therapy expanding into earlier treatment settings. That success triggered a wave of acquisitions, with Eli Lilly completing its purchase of POINT Biopharma on 27 December 2023 (Lilly release) and Bristol Myers Squibb and AstraZeneca following in 2024, so that several of the world’s largest pharmaceutical companies now own radiopharmaceutical developers and isotope capabilities. The result is a pipeline aimed at many more cancers and an industry scaling rapidly. The exclusive chapter of this report ledgers isotope supply against projected demand, because isotope availability has become the binding constraint on growth.

Which tracers and isotope therapies sit inside the USD 10.1 billion radiopharmaceutical total?

The USD 10.1 billion covers about 4.2 million oncology radiopharmaceutical doses in 2025 at USD 2,400 each: diagnostic PET and SPECT cancer tracers, lutetium-177 therapies, alpha emitter therapies, and the isotope supply and radiopharmacy services behind them. Cardiac and bone imaging outside cancer, scanners, external beam radiotherapy and brachytherapy are excluded.

The oncology radiopharmaceuticals study covers radiopharmaceuticals used to diagnose and treat cancer. Diagnostic PET and SPECT oncology tracers cover imaging agents used to detect, stage and select patients for treatment, including fluorodeoxyglucose, prostate specific membrane antigen tracers and other targeted imaging agents. Lutetium-177 targeted therapies cover radioligand therapies using the beta emitting isotope lutetium-177, including approved treatments for prostate cancer and neuroendocrine tumours and pipeline agents. Alpha emitter therapies cover treatments using alpha emitting isotopes such as radium-223 and actinium-225, which deliver more intense, shorter range radiation. Isotope supply and radiopharmacy services cover the production and supply of medical isotopes and the radiopharmacies that prepare and distribute doses. Non oncology nuclear medicine, such as cardiac and bone imaging outside cancer, imaging equipment such as PET and SPECT scanners, external beam radiotherapy, and brachytherapy sit outside the boundary. Value is measured at the realised price of doses and associated services. The model also splits oncology radiopharmaceutical revenue by cancer type, between prostate cancer, neuroendocrine tumours and other solid tumours in development, and by modality, between diagnostic imaging, beta emitter therapy and alpha emitter therapy.

Why is isotope supply the binding constraint on radioligand therapy?

Isotope supply binds because lutetium-177 and actinium-225 decay within days, cannot be stockpiled and come from a small number of reactors and accelerators. Oncology radiopharmaceutical doses must grow 11.0% a year, from about 4.2 million in 2025 to about 11.9 million in 2035, and every one of them must be made shortly before use.

The physics explains it: radioactive isotopes decay, cannot be stockpiled, and are produced in a small number of facilities, so supply must grow in step with demand in real time. Lutetium-177 is produced in nuclear research reactors or through other routes, then purified, combined with the targeting molecule and shipped to hospitals within days before it decays. A limited number of reactors worldwide can produce it, several of them ageing, and unplanned outages have disrupted supply. Actinium-225, the most promising alpha emitter for many pipeline therapies, is even scarcer, historically produced in tiny quantities from legacy nuclear materials, and scaling its production requires new methods and facilities that are only now being built. Because every dose must be manufactured shortly before use, supply chains are complex, time critical and vulnerable to disruption. This is why pharmaceutical companies acquiring radiopharmaceutical developers have also invested heavily in isotope production and manufacturing capacity, and why isotope producers have become strategically important. For this market, it means that growth in doses depends on the pace at which isotope supply and dose manufacturing expand, not only on clinical demand.

What moves oncology radiopharmaceutical doses from 4.2 million to 11.9 million by 2035?

Four forces lift oncology radiopharmaceutical doses 11.0% a year on the Douglas Insights model: label expansion into earlier treatment lines, a pipeline aimed at new cancers, theranostic imaging that must precede every therapy, and pharmaceutical capital. A 3.0% yearly rise in price per dose, as therapies gain share, takes revenue growth to 14.33%.

Earlier treatment lines are the first driver. On 28 March 2025 the FDA expanded Pluvicto to PSMA-positive metastatic castration-resistant prostate cancer patients who can delay taxane chemotherapy, based on the 468-patient PSMAfore trial, where median radiographic progression-free survival was 9.3 months against 5.6 months on a switch of hormone therapy (FDA notice). Moving a lutetium-177 therapy before chemotherapy enlarges the eligible patient pool, the main reason lutetium-177 therapies, 36% of 2025 revenue or USD 3.63 billion, grow fastest of the four categories.

The pipeline is the second driver. Radiopharmaceuticals targeting breast, lung, colorectal and other cancers are in clinical development; RayzeBio’s actinium-225 agent RYZ101 is in a phase 3 trial in neuroendocrine tumours and a phase 1b study in extensive-stage small cell lung cancer. In breast cancer, approved radioligands would enter a field already crowded with the agents sized in our Targeted Therapy for Breast Cancer Market report.

Theranostic diagnostics are the third driver. Each radioligand therapy requires diagnostic imaging, sized in the Diagnostic Imaging Market report, to select patients and monitor response, so therapy growth pulls through targeted tracers. Diagnostic PET and SPECT oncology tracers already hold 44% of 2025 revenue, USD 4.44 billion, the largest category.

Pharmaceutical investment is the fourth driver. The two 2024 actinium-225 deals alone, Bristol Myers Squibb’s USD 4.1 billion for RayzeBio and AstraZeneca’s USD 2.4 billion for Fusion, committed about USD 6.5 billion, bringing development capability, manufacturing and commercial reach that small radiopharmaceutical developers lacked.

Will isotope shortages, treatment-room capacity or payers cap radioligand growth?

Any of the three could, and together they define the supply-constrained scenario, in which oncology radiopharmaceutical doses grow 7.0% a year instead of 11.0% and the market reaches about USD 23.2 billion in 2035 rather than USD 38.5 billion. Isotope supply is the most binding, followed by nuclear medicine capacity and reimbursement.

Each restraint is modelled. Isotope supply is the most binding: limited reactor capacity, scarcity of actinium-225 and the time critical nature of production cap how many doses can be delivered and have caused shortages. Infrastructure and workforce are second: administering radiopharmaceutical therapy requires nuclear medicine facilities, trained physicians, radiation safety arrangements and in some cases patient isolation, and capacity in many hospitals is limited, creating bottlenecks in patient access. Clinical and reimbursement risk is third: pipeline agents may fail in trials, and high prices for therapies raise reimbursement questions in cost conscious health systems.

Do diagnostic tracers or lutetium-177 therapies earn more radiopharmaceutical revenue?

Diagnostic tracers earn more today: PET and SPECT oncology tracers hold 44% of 2025 oncology radiopharmaceutical revenue, USD 4.44 billion, against 36% or USD 3.63 billion for lutetium-177 therapies. Lutetium-177 therapies grow fastest, though, because label expansions such as the March 2025 Pluvicto approval move them into earlier lines at tens of thousands of dollars per dose.

Diagnostic PET and SPECT oncology tracers lead on the large volume of cancer imaging procedures, including high value targeted tracers. Lutetium-177 targeted therapies carry very high value per dose and gain as new agents are approved. Alpha emitter therapies account for 12%, USD 1.21 billion, a smaller share today but with substantial pipeline potential once actinium-225 supply scales. Isotope supply and radiopharmacy services contribute 8%, USD 806 million. Each radiopharmaceutical category is modelled through 2035 by region.

Why does North America take 52% of radiopharmaceutical revenue while Asia Pacific grows fastest?

North America takes 52% of 2025 oncology radiopharmaceutical revenue, USD 5.24 billion, because therapies such as Pluvicto were approved there first and sell at high prices through dense nuclear medicine networks. Asia Pacific grows fastest, at 17.2% a year from USD 1.51 billion, as Japan, China, South Korea, Australia and India add capacity and approvals.

North America grows 13.7% a year to about USD 18.9 billion in 2035, reflecting early approvals, high prices, extensive nuclear medicine infrastructure and rapid adoption of radioligand therapy. Europe holds 28%, USD 2.82 billion, at 13.6%, with strong nuclear medicine traditions, particularly in Germany, and growing therapy use. Asia Pacific reaches about USD 7.39 billion in 2035. The Middle East contributes USD 252 million at 16.0%, Latin America USD 181 million at 14.6% and Africa USD 70.6 million at 13.0%. Six regional radiopharmaceutical models sum to the global figure, with country tables in the Excel model.

Which companies lead oncology radiopharmaceuticals, from Novartis to the actinium-225 buyers?

Novartis leads oncology radiopharmaceuticals through its two approved lutetium-177 therapies, with Pluvicto’s March 2025 FDA expansion widening its prostate cancer lead. Three drugmakers bought their way in between December 2023 and June 2024: Eli Lilly with POINT Biopharma, Bristol Myers Squibb with RayzeBio for USD 4.1 billion and AstraZeneca with Fusion for USD 2.4 billion.

Novartis is the leading company in radioligand therapy, marketing approved lutetium-177 therapies for prostate cancer and neuroendocrine tumours and having built manufacturing and isotope capabilities. Bayer markets radium-223 for prostate cancer. Eli Lilly, AstraZeneca and Bristol Myers Squibb have acquired radiopharmaceutical developers and are advancing pipelines, including actinium-225 based agents. Lantheus supplies diagnostic imaging agents including prostate specific membrane antigen PET tracers, and Telix, Curium, GE HealthCare, Cardinal Health and others supply diagnostic agents, radiopharmacy services and isotopes. Isotope producers, research reactors and specialist companies supply lutetium-177 and actinium-225. The competitive chapter profiles each company’s approved products, pipeline, isotope supply position and manufacturing capacity. No leader share is stated on this page because company revenue by category is not split out in the model’s public figures.

Why does the average radiopharmaceutical dose cost USD 2,400 and keep rising?

Oncology radiopharmaceuticals average USD 2,400 per dose in 2025, rising 3.0% a year to about USD 3,230 by 2035, because therapy doses priced in the tens of thousands of dollars take a growing share of a volume still dominated by diagnostic tracers costing hundreds to a few thousand dollars.

That USD 2,400 average blends two very different categories. Diagnostic doses typically cost from hundreds to a few thousand dollars depending on the tracer, with targeted tracers priced well above conventional agents. Therapeutic doses of radioligand therapy cost tens of thousands of dollars each, and a course usually involves several doses, so a full treatment course is priced similarly to other advanced cancer therapies. Because therapies account for a rapidly growing share of doses, the average price per dose rises over the forecast, which is the reason for the positive price leg. Pricing is shaped by reimbursement negotiations with payers, which vary by country, and by manufacturing and isotope costs. The pricing chapter publishes price bands by product category and region.

How far apart do the isotope-constrained and pipeline-breakthrough cases land by 2035?

By 2035 oncology radiopharmaceuticals land between about USD 23.2 billion and USD 57.5 billion, around a USD 38.5 billion base case. The spread depends on whether actinium-225 supply scales and whether more therapies follow Pluvicto’s March 2025 move into earlier treatment lines, which together set dose growth between 7.0% and 14.0% a year.

The base case carries 11.0% growth in doses and 3.0% growth in price per dose for a 14.33% revenue CAGR and USD 38.5 billion in 2035. The supply-constrained scenario, in which isotope production and treatment capacity scale slowly and pipeline agents disappoint, sets the legs at 7.0% and 1.6%, landing near USD 23.2 billion. The pipeline-breakthrough scenario, in which multiple new cancer indications are approved, actinium-225 supply scales and therapies move into earlier lines, sets them at 14.0% and 4.4%, carrying the market to about USD 57.5 billion. Each 1-point change in dose growth moves the 2035 figure by roughly USD 3.37 billion.

Which drug approvals and radiation licences govern oncology radiopharmaceuticals?

Oncology radiopharmaceuticals answer to three regimes: drug regulators approve each product and each new indication, nuclear and radiation regulators license the facilities and staff that make and give the doses, and payers decide reimbursement. The FDA’s 28 March 2025 Pluvicto label expansion shows how a single indication decision widens the treatable population.

Three layers matter. Drug approval regulation comes first: radiopharmaceuticals must be approved as drugs, with clinical evidence of safety and efficacy, and approvals of new indications drive market expansion. Radiation safety and nuclear regulation is second: production, transport, handling, administration and disposal of radioactive materials are subject to stringent nuclear and radiation protection regulation, including licensing of facilities and staff, which affects the capacity to deliver therapies. Reimbursement and health technology assessment are third: payers assess the value of high cost therapies, and reimbursement decisions determine patient access, particularly in health systems with strict cost effectiveness thresholds. The regulatory chapter maps these requirements by jurisdiction.

What will actinium-225 unlock for alpha emitter cancer therapy?

Actinium-225 unlocks the alpha emitter category, 12% of 2025 oncology radiopharmaceutical revenue or USD 1.21 billion, and the pipelines behind the largest recent deals: Bristol Myers Squibb’s RayzeBio and AstraZeneca’s Fusion were both actinium-225 platforms. How fast actinium-225 production scales decides how quickly that pipeline value reaches patients.

Actinium-225 is widely seen as the key to the next phase of radiopharmaceutical growth, and its supply is the single most important variable for the pipeline. Alpha emitting isotopes such as actinium-225 deliver far more energy over a much shorter distance than beta emitters such as lutetium-177, which means they can kill cancer cells more potently while affecting less surrounding tissue, and they may work in patients whose cancers have become resistant to beta therapies. Many of the most promising pipeline radiopharmaceuticals, including those acquired in the recent wave of deals, use actinium-225. But actinium-225 has historically been available only in very small quantities, and producing it at the scale needed for widespread therapy requires new production routes, including accelerators and reactors using new target materials, that are being developed and built now. If supply scales on schedule, alpha therapies could become a large part of the market in the 2030s; if it lags, pipeline agents will be constrained regardless of clinical results. The model treats alpha emitters as a growing category whose pace depends on supply, with the pipeline breakthrough scenario reflecting successful scale up.

Douglas Exclusive: the isotope supply and capacity ledger

The isotope supply and capacity ledger is a Douglas Insights model and estimate, not an official register of isotope production. Its demand side starts from public records like the four regulator and company releases linked in this report, and capacity or demand figures that producers and drugmakers have not published are Douglas Insights estimates.

The ledger sets out, by isotope and producer, current and planned production capacity for lutetium-177, actinium-225 and diagnostic isotopes, reactor and accelerator status, dose manufacturing capacity, and projected demand from approved and pipeline therapies, identifying supply gaps by year and converting clinical demand into deliverable doses and revenue by category and region. Licence holders receive it as a maintained tab in the Excel model.

Methodology and receipts

The oncology radiopharmaceuticals model is built bottom-up in numbers: about 4.2 million doses in 2025 at an average realised USD 2,400 per dose gives USD 10.1 billion, split into four product categories and six regional models that sum to the global figure. Doses then grow 11.0% a year to about 11.9 million and price per dose 3.0% a year, giving USD 38.5 billion in 2035.

Inputs are cancer imaging procedure volumes by tracer and region, patients treated with approved radioligand therapies and projected uptake of pipeline agents by indication, doses per course, isotope supply constraints, and realised prices from company disclosures and reimbursement data, with non oncology nuclear medicine, imaging equipment, external beam radiotherapy and brachytherapy excluded. Every figure carries a numbered source and a confidence grade in the fact sheet above, and the working model ships with every licence. The next scheduled review of this study is September 2027.